KPV
Preclinical ResearchKPV
A tripeptide fragment of alpha-MSH researched for its powerful anti-inflammatory and gut healing properties. Particularly promising for IBD and skin inflammation.
Dose
50-500 mcg
Route
Oral, Topical, SubQ injection
Cycle
4-12 weeks, as per research protocol
Storage
Refrigerated (2-8°C / 36-46°F) or frozen (-20°C / -4°F) away from light
What is KPV?
KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) that has garnered significant research interest due to its potent anti-inflammatory and immunomodulatory properties. It is commonly investigated for its potential in conditions characterized by inflammation, particularly in the gastrointestinal tract and skin. Research suggests KPV exerts its effects by inhibiting the activation of NF-κB, a key regulator of inflammatory responses, reducing T-cell proliferation, and blocking inflammatory cell migration. This mechanism of action positions KPV as a promising subject for studies related to inflammatory bowel disease (IBD), psoriasis, and various wound healing scenarios. Its small size allows for various administration routes, including oral, topical, and subcutaneous injection, which are commonly discussed in research contexts.
Key Benefits
- Anti-inflammatory
- Gut healing
- Skin inflammation reduction
- Wound healing support
- IBD research potential
Mechanism of Action
- Inhibits NF-kB activation
- Reduces T-cell proliferation
- Blocks inflammatory cell migration
- Anti-inflammatory signaling
Best For
- Inflammatory gut condition research
- Skin inflammation research
- Autoimmune research
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
361.4 g/mol
Length
3
Type
Linear Peptide
Amino acid sequence
Lys-Pro-Val
Lysine-Proline-Valine
Research Indications
Inflammatory Bowel Disease (IBD) Research
KPV is extensively studied for its anti-inflammatory effects in models of IBD, including Crohn's disease and ulcerative colitis, where it demonstrates potential to reduce gut inflammation and promote mucosal healing.
Gastric Ulcer Research
Preclinical studies suggest KPV may contribute to the healing of gastric ulcers by modulating inflammatory responses and potentially enhancing protective factors in the gastric mucosa.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acute Inflammatory Response Mitigation (SubQ) | 100-250 mcg | Once daily | Subcutaneous injection |
| Chronic Gut Inflammation (Oral) | 250-500 mcg | Once or twice daily | Oral solution or capsule |
| Topical Skin Inflammation (Topical) | 0.01% - 0.1% concentration in cream or gel | Once or twice daily | Topical application |
| Wound Healing Enhancement (SubQ/Topical) | 100-250 mcg SubQ; 0.05% topical | Once daily (SubQ), Twice daily (Topical) | Subcutaneous injection and/or Topical application |
| Systemic Anti-inflammatory Effects (SubQ) | 100-300 mcg | Once daily | Subcutaneous injection |
Specific timing considerations for KPV research protocols often depend on the condition being investigated. For acute inflammatory states, daily administration might be prioritized. For chronic conditions or tissue repair, consistent daily dosing over several weeks is commonly discussed.
Peptide Interactions
- Monitor Combination
Corticosteroids
While both possess anti-inflammatory properties, combining with corticosteroids may lead to additive effects, requiring careful monitoring for efficacy and potential side effects.
- Monitor Combination
NSAIDs
May have additive anti-inflammatory effects. Monitoring for gastrointestinal distress, common with NSAIDs, and assessing combined impact on inflammation is advised.
- Use Caution
Immunosuppressants
KPV modulates immune responses; combining with other immunosuppressants should be done with caution and close monitoring for over-suppression or altered efficacy.
- Compatible
Antibiotics
No direct interactions commonly reported in research; may be used concomitantly, especially in cases where infection and inflammation coexist.
- Synergistic
Probiotics
In gut health research, KPV's anti-inflammatory action may complement the gut-modulating effects of probiotics, potentially enhancing beneficial outcomes.
How to Reconstitute
- 1Gather KPV vial, bacteriostatic water (BW), sterile syringes, and alcohol wipes.
- 2Wipe the tops of both the KPV vial and the BW vial with alcohol wipes.
- 3Draw the desired amount of BW (e.g., 1-2 mL) into a sterile syringe.
- 4Slowly inject the BW into the KPV vial, aiming the stream at the glass side, not directly onto the powder.
- 5Gently swirl the vial (do not shake) until the powder is completely dissolved. This may take several minutes.
- 6Store the reconstituted solution in the refrigerator.
What to Expect
- Week 1-2: Initial observations of reduced inflammatory markers or localized symptom improvement may begin, particularly with topical or subcutaneous routes.
- Week 2-4: More consistent reductions in inflammation and initial signs of tissue healing, especially in models of gut or skin inflammation.
- Week 4-8: Potential for more noticeable and sustained improvements in symptoms related to chronic inflammatory conditions, such as reduced discomfort or improved skin integrity.
- Week 8-12: Continued progression in tissue repair and sustained anti-inflammatory effects. Researchers often monitor for long-term benefits and potential for relapse post-treatment.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Minimal reported | Rare | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.